Progress of NGF-TrkA Signaling in Tumors and Molecular Targeted Therapy_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHENGMing-jia ^1,2 ,  LINYi-dan ¹

1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Stomatology, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

LINYi-dan, Email: yidanlin-kin@hotmail.com

Keywords：

TrkA; Nerve growth factor; Neoplasm

DOI：

10.7507/1007-4848.20150070

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Nerve growth factor (NGF), a pleiotropic molecule, can bind to specific tyrosine kinase receptor TrkA and induce a number of biological activities. NGF and TrkA are involved not only in the development of nervous system, but also in the pathogenesis of different types of malignancies. Studies have shown that NGF and its TrkA receptor are closely related to carcinogenesis, proliferation, angiogenesis and metastasis of solid tumors. Thus, inhibitors targeting at TrkA may provide a new approach for cancer treatment, and some of them have already been applied in clinical trials. This review summarizes the involvement of NGF-TrkA in tumors and related progress of molecular targeted therapies.

Citation： CHENGMing-jia, LINYi-dan. Progress of NGF-TrkA Signaling in Tumors and Molecular Targeted Therapy. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2015, 22(3): 261-264. doi: 10.7507/1007-4848.20150070 Copy

1.	Aloe L, Chaldakov GN.The multiple life of nerve growth factor:Tribute to Rita Levi-Montalcini (1909-2012).Balkan Med J, 2013, 30(1):4-7.
2.	Pierotti MA, Greco A.Oncogenic rearrangements of the NTRK1/NGF receptor.Cancer Lett, 2006, 232(1):90-98.
3.	Vaishnavi A, Capelletti M, Le AT, et al.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Nat Med, 2013, 19(11):1469-1472.
4.	Prakash Y.Neurotrophins in lung health and disease.Expert Rev Respir Med, 2010, 4(3):395-411.
5.	Hondermarck H.Neurotrophins and their receptors in breast cancer.Cytokine Growth Factor Rev, 2012, 23(6):357-365.
6.	Tsunoda S, Okumura T, Ito T, et al.Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma.Br J Cancer, 2006, 95(3):322-330.
7.	Ichim GT, Mehlen P.Neurotrophins and cell death.Exp Cell Res, 2012, 318(11):1221-1228.
8.	Nico B.Nerve growth factor as an angiogenic factor.Microvasc Res, 2008, 75(2):135-141.
9.	Kim JY, Park H.Effects of Tropomyosin-related kinase a inhibitors on the proliferation of human lung cancer cells.Bull Korean Chem Soc, 2013, 34(4):1293-1295.
10.	Park MJ, Kwak HJ, Lee HC, et al.Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor.J Biol Chem, 2007, 282(42):30485-30496.
11.	Voss MJ, M?ller MF, Powe DG, et al.Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.BMC Cancer, 2011, 11:158.
12.	Romon R, Adriaenssens E, Lagadec C, et al.Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways.Mol Cancer, 2010, 9:157.
13.	Dolle JP, Rezvan A, Allen FD, et al.Nerve growth factor-induced migration of endothelial cells.J Pharmacol Exp Ther, 2005, 315(3):1220-1227.
14.	Koutras KA.Bevacizumab in the treatment of breast cancer.Cancer Treat Rev, 2010, 36(1):75-82.
15.	Liebig C.Perineural invasion in cancer:a review of the literature.Cancer, 2009, 115(15):3379-3391.
16.	Marchesi F.Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis.Cytokine Growth Factor Rev, 2010, 21(1):77-82.
17.	Okada Y, Eibl G, Guha S, et al.Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells.Clin Exp Metastasis, 2004, 21(4):285-292.
18.	Nagy JA, Feng Dian, Vasile E, et al.Permeability properties of tumor surrogate blood vessels induced by VEGF-A.Laboratory Investigation, 2006, 86(8):767-780.
19.	Bloom AP, Jimenez-Andrade JM, Taylor RN, et al.Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers.J Pain, 2011, 12(6):698-711.
20.	Mckelvey LD, O'keeffe GW.Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.J Neurochem, 2013, 124(3):276-289.
21.	Marshall JL, Kindler H, Deeken J, et al.Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.Invest New Drugs, 2005, 23(1):31-37.
22.	Undevia SD, Vogelzang NJ, Mauer AM, et al.PhaseⅠclinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.Invest New Drugs, 2004, 22(4):449-458.
23.	Thress K, Macintyre T, Wang H, et al.Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.Mol Cancer Ther, 2008, 6(12):180.
24.	Albanese C, Alzani R, Amboldi N, et al.Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with Broad-Spectrum antitumor efficacy.Mol Cancer Ther, 2010, 9(8):2243-2254.
25.	Chiarenza A, Lazarovici P, Lempereur L, et al.Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7.Cancer Res, 2001, 61(7):3002-3008.
26.	Festuccia C.Her2 crosstalks with TrkA in a subset of prostate cancer cells:rationale for a guided dual treatment.Prostate, 2009, 69(4):337-345.

1. Aloe L, Chaldakov GN.The multiple life of nerve growth factor:Tribute to Rita Levi-Montalcini (1909-2012).Balkan Med J, 2013, 30(1):4-7.
2. Pierotti MA, Greco A.Oncogenic rearrangements of the NTRK1/NGF receptor.Cancer Lett, 2006, 232(1):90-98.
3. Vaishnavi A, Capelletti M, Le AT, et al.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Nat Med, 2013, 19(11):1469-1472.
4. Prakash Y.Neurotrophins in lung health and disease.Expert Rev Respir Med, 2010, 4(3):395-411.
5. Hondermarck H.Neurotrophins and their receptors in breast cancer.Cytokine Growth Factor Rev, 2012, 23(6):357-365.
6. Tsunoda S, Okumura T, Ito T, et al.Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma.Br J Cancer, 2006, 95(3):322-330.
7. Ichim GT, Mehlen P.Neurotrophins and cell death.Exp Cell Res, 2012, 318(11):1221-1228.
8. Nico B.Nerve growth factor as an angiogenic factor.Microvasc Res, 2008, 75(2):135-141.
9. Kim JY, Park H.Effects of Tropomyosin-related kinase a inhibitors on the proliferation of human lung cancer cells.Bull Korean Chem Soc, 2013, 34(4):1293-1295.
10. Park MJ, Kwak HJ, Lee HC, et al.Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor.J Biol Chem, 2007, 282(42):30485-30496.
11. Voss MJ, M?ller MF, Powe DG, et al.Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.BMC Cancer, 2011, 11:158.
12. Romon R, Adriaenssens E, Lagadec C, et al.Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways.Mol Cancer, 2010, 9:157.
13. Dolle JP, Rezvan A, Allen FD, et al.Nerve growth factor-induced migration of endothelial cells.J Pharmacol Exp Ther, 2005, 315(3):1220-1227.
14. Koutras KA.Bevacizumab in the treatment of breast cancer.Cancer Treat Rev, 2010, 36(1):75-82.
15. Liebig C.Perineural invasion in cancer:a review of the literature.Cancer, 2009, 115(15):3379-3391.
16. Marchesi F.Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis.Cytokine Growth Factor Rev, 2010, 21(1):77-82.
17. Okada Y, Eibl G, Guha S, et al.Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells.Clin Exp Metastasis, 2004, 21(4):285-292.
18. Nagy JA, Feng Dian, Vasile E, et al.Permeability properties of tumor surrogate blood vessels induced by VEGF-A.Laboratory Investigation, 2006, 86(8):767-780.
19. Bloom AP, Jimenez-Andrade JM, Taylor RN, et al.Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers.J Pain, 2011, 12(6):698-711.
20. Mckelvey LD, O'keeffe GW.Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.J Neurochem, 2013, 124(3):276-289.
21. Marshall JL, Kindler H, Deeken J, et al.Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.Invest New Drugs, 2005, 23(1):31-37.
22. Undevia SD, Vogelzang NJ, Mauer AM, et al.PhaseⅠclinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.Invest New Drugs, 2004, 22(4):449-458.
23. Thress K, Macintyre T, Wang H, et al.Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.Mol Cancer Ther, 2008, 6(12):180.
24. Albanese C, Alzani R, Amboldi N, et al.Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with Broad-Spectrum antitumor efficacy.Mol Cancer Ther, 2010, 9(8):2243-2254.
25. Chiarenza A, Lazarovici P, Lempereur L, et al.Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7.Cancer Res, 2001, 61(7):3002-3008.
26. Festuccia C.Her2 crosstalks with TrkA in a subset of prostate cancer cells:rationale for a guided dual treatment.Prostate, 2009, 69(4):337-345.

Previous Article
腹部創傷后并發癥的防治
Next Article
CT檢查在腹部創傷診療中的應用價值

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Progress of NGF-TrkA Signaling in Tumors and Molecular Targeted Therapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content